Find investors
← Back to all investors
NM
ResearchedAngel Investors

Nicholas Mekas

Angel InvestorsSeed Round
Pitch Nicholas

Get their honest, personalized take on your startup.

Sign in to pitch Nicholas

At a glance

Full Name
Nicholas G. Mekas
Title
Vice President, Investment Banking (healthcare) — most recently at Leerink Partners; earlier an Associate at MTS Health Partners / WindRose Health Investors
Firm
uRefer (early career, Ann Arbor referral-marketing startup) / currently in healthcare investment banking
Firm Type
Angel Investor (as classified in startup-investor databases)
Investment Stage
Seed (per investor-database listing)
Sector Focus
Background spans ad-tech / marketing-technology startups and, in his finance career, healthcare
Geographic Focus
United States (Michigan, New York, and Boston-area ties)
Location
Boston, Massachusetts (current); previously Ann Arbor, MI and New York, NY

Background

Nicholas Mekas earned a Bachelor of Business Administration in Entrepreneurship & Finance from the University of Michigan's Stephen M. Ross School of Business (his recorded enrollment period is roughly 2008–2010). His University of Michigan roots and the Ann Arbor "734" area-code phone numbers tie him to southeastern Michigan's startup community, where his early career began.

That early career ran through marketing-technology and venture-oriented companies. He is associated (via his `[hidden]` email) with uRefer, an Ann Arbor referral-marketing startup founded in 2007 by Richard Beedon; uRefer built software to help companies run customer-referral and "advocate relationship management" programs and was later rebranded Amplifinity. He subsequently worked at HookLogic, Inc., the New York–based pioneer of retail/e-commerce performance advertising (partners included Walmart, Target, Best Buy and Expedia), which Criteo acquired for roughly $250 million in November 2016. Public profiles also list a stint as a financial analyst at RSVP Capital / RSVP Ventures.

He then moved into healthcare-focused finance, appearing as an Associate at MTS Health Partners and WindRose Health Investors in New York, and most recently as a Vice President at Leerink Partners, a Boston-based investment bank focused exclusively on healthcare. FINRA BrokerCheck records a Nicholas G. Mekas (CRD #6311832) registered in the securities industry since 2014 at Leerink Partners in Boston, holding Series 7, 63 and 79 licenses.

It is on the strength of this entrepreneurial-plus-finance background that startup-investor databases (e.g., Foundersuite) list him as an angel investor active at the seed stage. Note that the "angel investor / seed" framing comes from those aggregator listings rather than from a publicly documented, named personal investment portfolio.

Investment Thesis & Focus

  • Listed in investor databases as an angel investor focused on seed-round financings.
  • Professional and operating experience clusters around marketing technology / ad-tech and e-commerce (uRefer, HookLogic) and, separately, healthcare through his investment-banking career (MTS Health Partners, WindRose, Leerink).
  • No publicly stated personal investment thesis, check-size range, or formal mandate could be verified; treat the "seed-stage angel" label as a database classification, not a self-published thesis.

Notable Investments

  • No specific, individually attributed angel investments by Nicholas Mekas are publicly documented in the sources reviewed. (His name appears tied to companies he *worked at* — uRefer/Amplifinity and HookLogic — rather than to disclosed personal cap-table positions.)
  • For context on the companies in his orbit:
  • uRefer / Amplifinity — Ann Arbor referral-marketing ("advocate relationship management") software startup, founded 2007.
  • HookLogic — New York e-commerce performance-advertising exchange; acquired by Criteo for ~$250M in November 2016.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.